Posted by AGORACOM-JC
at 7:43 AM on Tuesday, January 26th, 2021
Partnered with Empower Clinics to establish the Re-open Vancouver coalition with the goal of obtaining an approved end-to-end COVID-19 mitigation solution that can be presented to local, Provincial and Federal Government authorities on behalf of local stakeholders to help in the re-opening of Vancouver’s travel and tourism industry, including Vancouver’s cruise industry.
Will lead a coalition to deploy the necessary infrastructure needed to enable the economic recovery of the local Vancouver economy.
Under the leadership of Loop and Empower, the Re-open Vancouver coalition will focus on a science and data-driven approach to delivering an integrated end-to-end solution worthy of re-opening Vancouver’s robust tourism industry, including its convention center and cruise ship industry.
According to Your Canada , Vancouver’s tourism industry generates approximately 15 million unique visitors per year.
VANCOUVER, British Columbia, Jan. 26, 2021 — Loop Insights Inc. (TSXV:MTRX OTCQB:RACMF) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated venue management solutions to physical brick and mortar operators, is pleased to announce the Company has partnered with Empower Clinics to establish the Re-open Vancouver coalition with the goal of obtaining an approved end-to-end COVID-19 mitigation solution that can be presented to local, Provincial and Federal Government authorities on behalf of local stakeholders to help in the re-opening of Vancouver’s travel and tourism industry, including Vancouver’s cruise industry.
Loop Insights and Empower Clinics will lead a coalition to deploy the necessary infrastructure needed to enable the economic recovery of the local Vancouver economy. Under the leadership of Loop and Empower, the Re-open Vancouver coalition will focus on a science and data-driven approach to delivering an integrated end-to-end solution worthy of re-opening Vancouver’s robust tourism industry, including its convention center and cruise ship industry. According to Your Canada , Vancouver’s tourism industry generates approximately 15 million unique visitors per year.
Following the Canadian federal government’s announcement that all international travelers will be required to provide proof of a negative COVID-19 test in order to enter the country, Loop and Empower feel the two companies are uniquely positioned to provide a combined solution in the form of a digital Wallet pass with bank-level security and privacy that can be offered to travelers visiting Vancouver.
Steven McAuley, Chairman, and CEO of Empower stated “Benefiting from the leadership of two local Vancouver public companies, with the support of significant private and public sector participants, Re-open Vancouver is confident it will demonstrate how crucial our efforts are to the economy of the City of Vancouver, the Province of B.C. and Canada. In partnership with Loop Insights, we have market-proven tools, services, testing products, and healthcare infrastructure to make this happen now.”
Tourism Industry Facing $3.3 Trillion In Global Losses Due to Closures
According to the United Nations Conference on Trade and Development (UNCTAD), the tourism industry stands to lose up to $3.3 trillion in revenue due to closures if the industry is to remain shuttered for a year. In an effort to prevent these losses, Loop Insights will continue to work with Empower to deploy its integrated venue management platform to protect industries in need of robust safety and security protocols. To date, the Re-open Vancouver Coalition has entered into conversations with leading stakeholders in the tourism, travel, and hospitality industries.
Loop Insights CEO Rob Anson stated: “Many key provincial stakeholders in the travel, tourism, and hospitality sector have recently reached out as a result of our most recent successes deploying Loop’s venue management platform. Operators are in desperate need of a seamless and transformative solution that kickstarts the economic recovery process. Along with Empower Clinics, we will look to work with industries’ best of breed partners to deliver a unified solution that ensures best practice considerations in regards to the health, safety, and wellbeing of local residents and tourists alike.“
Loop Insights first partnered with Empower Clinics in October 2020 to provide an end-to-end COVID-19 mitigation solution complete with venue tracing, real-time automated guest exposure notifications, and testing procedures based on published guidelines.
Posted by AGORACOM-JC
at 7:58 AM on Thursday, January 21st, 2021
Announced significant expansion of our KAI Medical Laboratory in Dallas, Texas in anticipation of projected growth in COVID-19 testing requirements in the U.S., Canada and international markets.
In addition, Empower has filed a Medical Device Establishment Licence with Health Canada for the purposes of importing, distributing and selling our KAI Medical COVID-19 Saliva Test, which has experienced immediate success since it’s launch on December 15, 2020 in the United States and reported on January 7, 2021.
VANCOUVER, BC / January 21, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“) an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce significant expansion of our KAI Medical Laboratory in Dallas, Texas in anticipation of projected growth in COVID-19 testing requirements in the U.S., Canada and international markets.
In addition, Empower has filed a Medical Device Establishment Licence (“MDEL”) with Health Canada for the purposes of importing, distributing and selling our KAI Medical COVID-19 Saliva Test (“KAI Saliva”), which has experienced immediate success since it’s launch on December 15, 2020 in the United States and reported on January 7, 2021.
KAI MEDICAL LABORATORY EXPANDING TO AT LEAST DOUBLE CURRENT SIZE IN ANTICIPATION OF ANTICIPATED GROWTH IN VOLUME
KAI Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and the travel industry. KAI experienced significant growth in its first quarter under Empower, with Q4 COVID-19 test kit volumes exceeding 6,000 units, far surpassing the 1,300 total units prior to acquisition.
Current run rate projections now indicate as follows:
January 2021 is expected to exceed 8,000 tests, surpassing all of Q4 2020
February 2021 could see daily rates hit 1,000 tests per day
March 2021 could see daily rates hit 2,000 tests per day
Empower Clinics CEO, Steven McAuley stated “Our investment in R&D is really starting to pay off for KAI Medical, starting with a new state-of-art laboratory information system to automate processes for the anticipated growth in volume. Next, we have hired three new scientists, increased administrative staff and are activating a call center to provide world-class customer support. Further, the investment in new test protocols such as the Kai Saliva test kit, combined with our Health Canada medical device licence, positions us to be a leader in the reactivation of travel for Canadians.”
Posting on Twitter to both @EmpowerClinics and @Agoracom with the any of the following hashtags #empowerclinics_QA, #CBDTQA, #CBDT_QA
Questions must be posted by no later than Wednesday, January 20th, 5PM EST.
With Empower Clinics Entering Growth Phase On Multiple Business Fronts, Chairman & CEO Steven McAuley Provides Shareholders With An Opportunity To Fully Participate In Company’s First AGORACOM Video Q&A
VANCOUVER, BC / January 19, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical clinics in USA and Canada, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce its first ever AGORACOM Video Q&A, which provides investors with the opportunity to submit questions for response by Chairman & CEO Steven McAuley.
Empower Clinics CEO Steven McAuley stated “With so much tremendous progress taking place for our company, as we head into what I expect to be our breakthrough and greatest year ever in 2021, I want to make sure shareholders have an opportunity to ask questions, receive answers directly from me and begin the process of regular engagement through our Verified Forum on AGORACOM. I am looking forward to engaging with shareholders and followers on the interview.”
VIDEO Q&A DETAILS
Shareholders are able to submit questions by either:
Posted by AGORACOM-JC
at 7:44 AM on Thursday, January 7th, 2021
Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas,TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and colleges
Announced the successful launch of our KAI Saliva PCR Test with our initial soft launch of 5,000 units sold out and the order of 25,000 additional units with a sales value of approximately $5,500,000.
Initial and overwhelming demand for KAI Saliva stemmed from our existing customers in film & television productions, the commercial sector, and concierge testing supported by Sun Valley Health in Arizona.
Given the early and significant success of KAI Saliva since its launch on December 15, 2020, Empower is extremely confident in the continued success of KAI Saliva with both existing and expanded commercial customers in this next run.
VANCOUVER, BC / January 7, 2021 / EMPOWER CLINICS INC. (CBDT:CSE)(8EC:Frankfurt)(EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce the successful launch of our KAI Saliva PCR Test (“KAI Saliva”) with our initial soft launch of 5,000 units sold out and the order of 25,000 additional units with a sales value of approximately $5,500,000.
INITIAL DEMAND FOR FIRST RUN KAI SALIVA CAME FROM EXISTING COMMERCIAL CUSTOMERS, INCLUDING FILM & TELEVISION PRODUCTIONS. DIRECT TO CONSUMER CHANNEL LAUNCH IMMINENT
Initial and overwhelming demand for KAI Saliva stemmed from our existing customers in film & television productions, the commercial sector, and concierge testing supported by Sun Valley Health in Arizona. Given the early and significant success of KAI Saliva since its launch on December 15, 2020, Empower is extremely confident in the continued success of KAI Saliva with both existing and expanded commercial customers in this next run.
Tags: covid19, Covid19 testing, CSE, Diagnos Inc, investments, Kai Medical Laboratory, small cap stocks, tsx Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca $EPWCF KAI Medical Laboratory Sells Out First 5,000 Units Of FDA EUA Approved Saliva #COVID-19 Test Kits. Issues Order For Next 25,000 KAI Saliva PCR Test Kits With Sales Value Of $5.5M. Discussions With Major Airlines Underway $WELL.ca $DOC.ca $DOCRF $VMD.ca
Posted by AGORACOM-JC
at 10:26 PM on Monday, December 21st, 2020
Sometimes, you just have to let the numbers speak for themselves. With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that any small cap Health & Wellness company would kill for … but then you add in that CBDT has now delivered growth in 5 (FIVE) successive financial reports (Q4, FY 2019, Q1, Q2 and Q3), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019.
Since that day Empower has made several announcements that grew the Company by several magnitudes again. From record testing contracts to new products, partnerships (We see you Loop Insights $MTRX + SimpliFlying) and a $5.5 MILLION injection from warrant proceeds (that is now closer to $6.8M), McAuley was building the foundations of a health & wellness powerhouse.
Finally, for all the new investors that have joined Empower in the last several weeks, McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which explains how McAuley has been able to guide Empower Clinics through the most disruptive environment in recent history and turn it into significant growth through Q4 2020 and the foundations to turn it into a powerhouse over the next 3 years.
If you MISSED Well Health and CloudMD, you really need to take a close look at Empower as the next great potential small cap health & wellness company.
Posted by AGORACOM-JC
at 4:16 PM on Thursday, December 17th, 2020
Acquisition Will Expand Company’s North American Footprint And Strengthen Vertical Integration From Patients To Laboratory, Strengthening Testing and Bubble Initiatives
Announced the execution of a definitive share purchase agreement dated December 16, 2020 to acquire Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc. dba Atkinson, and Momentum Health Inc.
Momentum Health operates a network of medical clinics with a team of healthcare professionals who provide para-medical care by applying a holistic and hands-on approach working with patients to unlock potential well-being.
Key services include physiotherapy, chiropractic, massage therapy, traditional Chinese medicine, athletic therapy and others.
Acquisition will include two standalone wellness clinics and five new co-located clinics in the Greater Toronto Area of Ontario, Canada, with immediate access to in excess of 20,000 patients.
VANCOUVER, BC / December 17, 2020 / Empower Clinics (CSE:CBDT)(OTC PINK:EPWCF)(FRA:8EC) (the “Company” or “Empower”), an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA and Health Canada approval, is pleased to announce the execution of a definitive share purchase agreement dated December 16, 2020 (the “Agreement“) to acquire Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc. dba Atkinson, and Momentum Health Inc. (collectively “Momentum Health“).
Steven McAuley, Chairman and CEO of Empower stated “The acquisition of Momentum Health will be a significant milestone for both Empower and its shareholders that we expect will provide Empower with a growing accretive business, as well as, a winning business model with plans for immediate expansion across the Greater Toronto Area, the province of Ontario and then nationwide in very rapid succession. It is anticipated that this immediate and rapid nationwide expansion plan will be made possible by combining the winning Momentum Health model with the financial, marketing and operational control resources already successfully deployed by Empower in building its US operations, including the successful win of a $1.2 million testing contract with a film and television studio within just 45 days of acquiring our KAI Medical Lab. Significant discussions are already underway with potential nationwide partners and we expect to have developments in the very near future.”
ACQUISITION INCLUDES 7 CLINICS IN GREATER TORONTO AREA WITH IMMEDIATE PLANS TO EXPAND “CLINIC-IN-CLINIC” MODEL ACROSS CANADA.
Momentum Health operates a network of medical clinics with a team of healthcare professionals who provide para-medical care by applying a holistic and hands-on approach working with patients to unlock potential well-being. Key services include physiotherapy, chiropractic, massage therapy, traditional Chinese medicine, athletic therapy and others. The full range of services can be viewed at www.momentumhealthclinic.com.
The acquisition will include two standalone wellness clinics and five new co-located clinics in the Greater Toronto Area of Ontario, Canada, with immediate access to in excess of 20,000 patients.
More importantly, it is expected that expansion will be at a very attractive and cost-effective model of opening “clinics-within-clinics” in which the Company proposes to partner with large care facilities to provide para-medical clinics inside the physical location of the primary care facility. This model results in a win-win for both Empower and the primary care facility partner as follows:
Substantially improved care for patients of the primary care facility
Significantly reduced start-up costs for Empower
Immediate access to the large patient base of the primary care facility
Immediate rental income for the primary care facility
With this proven winning model, the nationwide roll-out it is planned to commence immediately upon closing of the acquisition with expansion in the Greater Toronto Area, followed by expansion throughout Ontario and finally West through all Provinces with a standardized brand and technology platform.
Moreover, the acquisition includes incentives for the two Co-Founders of Momentum Health to open an additional 30 clinics across Canada.
CEO McAuley added “Having Dr. Rabinowitz and Dr. Tsimerman join me in leadership to rapidly expand Empower’s clinic footprint across Canada will be invaluable toward meeting our ambitious objectives.”
Momentum Co-Founder Dr. Robinowitz commented “Joining Empower provides us with the opportunity to scale an intricately designed health care model alongside the outstanding professionals currently on their team. This transaction will not only allow our current patients to have increased access to integrative care, we also strive to exponentially increase our patient base with strategic, nationwide expansion.”
Momentum Co-Founder Dr. Tsimerman commented “I am thrilled to be joining Empower Clinics with a shared vision of nationwide, truly integrative medical care based on patient – centric services. This unique opportunity allows us to provide an unparalleled patient experience and create a leading approach to modernized health care.”
TERMS OF ACQUISITION
Pursuant to the terms of the Agreement, Empower will pay the vendors of Momentum Health $275,000 cash at closing (including $44,648 to settle an outstanding debt of Momentum Health) with an additional $75,000 to be withheld as a holdback for adjustments, for an aggregate cash payment of $350,000. In addition, at closing, Empower will issue Dr. Jordan Rabinowitz and Dr. Aviv Tsimerman or their affiliates 5,128,204 common shares in the capital of Empower (at a deemed price of $0.0975 per share), 2,564,102 of which will be subject to contractual resale restrictions resulting in them being released quarterly from the date of closing in eight (8) equal instalments.
PERFORMANCE INCENTIVES TO OPEN 30 ADDITIONAL LOCATIONS
The acquisition also includes long-term performance incentives for Dr. Rabinowitz and Dr. Tsimerman. If, within 18 months from the closing date, the Company or its affiliates have opened and have operating an aggregate of ten (10) new clinic locations in Canada (“Milestone One”), each of Dr. Rabinowitz and Dr. Tsimerman shall be entitled to receive incentive stock options of Empower to purchase 1,875,000 common shares of Empower, vesting as follows:
1/3 immediately;
1/3 upon of the Company or its affiliates having opened and operating an aggregate of twenty (20) new clinic locations in Canada; and
1/3 upon of the Company or its affiliates having opened and operating an aggregate of thirty (30) new clinic locations in Canada.
ADDITIONAL DETAILS
Empower has agreed to enter into employment agreements with Dr. Rabinowitz and Dr. Tsimerman on closing of the acquisition, to lead the Canadian clinic expansion strategy.
Completion of the acquisition contemplated by the Agreement is subject to customary closing conditions which the Company anticipates being completed on or before December 21, 2020.
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
ABOUT EMPOWER:
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the Company’s nationwide rollout and timing and results of such rollout; the Company expecting the acquisition will provide Empower with a growing accretive business, as well as, a winning business model with plans for immediate expansion across the Greater Toronto Area, the province of Ontario and then nationwide in very rapid succession; the Company’s expectation for the costs of expansion; and the Company’s plans to partner with large care facilities to provide para-medical clinics inside the physical location of the primary care facility and the results of such model. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
Posted by AGORACOM-JC
at 7:32 AM on Monday, December 14th, 2020
Announce the receipt of in excess of $5,500,000 from the exercise of warrants up to December 11, 2020
The proceeds were received over the past four trading days as a result of strong equity market support for the momentum demonstrated by the Company
It serves as an indication of the strength of Empower’s shareholder base and its following
Company is pleased to report that our new website has been launched to reflect the Company’s pillars of growth in 2021 and beyond
VANCOUVER BC / December 14, 2020 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through its clinics, telemedicine platforms and as a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and validating novel COVID-19 testing protocols for CE, FDA and Health Canada approval is pleased to announce the following:
RECEIPT OF $5,500,000 + FROM THE EXERCISE OF WARRANTS ALLOWS EMPOWER TO CONTINUE TO EXECUTE WITH INCREASED STRENGTH
Empower is pleased to announce the receipt of in excess of $5,500,000 from the exercise of warrants up to December 11, 2020. The proceeds were received over the past four trading days as a result of strong equity market support for the momentum demonstrated by the Company. It serves as an indication of the strength of Empower’s shareholder base and its following.
The Company expects to generate meaningful revenue from its current and anticipated sales pipeline over the next 12 months, as well as, receive additional proceeds from further anticipated warrant exercises, the Company is confident it has the war chest necessary to pursue numerous opportunities. KAI medical laboratory continues to expand nationwide in the U.S., Empower is growing physician services and direct access to patients through new clinics expansions and the company will provide dynamic technology-based healthcare services to meet patient needs.
Steven McAuley, Chairman and CEO of Empower stated, “The timing of these warrant exercises could not be better as we head into our biggest growth phase ever, thanks to rapidly growing demand for our KAI Medical Lab COVID-19 testing solutions, as well as, the impending launch of our FDA approved KAI Saliva Test plus the pending clinic group acquisition in Canada. These proceeds significantly bolster our financial strength, resources and confidence necessary to aggressively pursue our growth strategies in 2021.”
EMPOWER LAUNCHES NEW WEBSITE TO BETTER REFLECT COMPANY’S 2021 DIRECTION
The Company is pleased to report that our new website has been launched to reflect the Company’s pillars of growth in 2021 and beyond, as well as, our defined vision as follows:
GROWTH PILLARS
Health & Wellness Is Our Purpose – Through our clinics in the US and telemedicine platform, our physicians treat patients in Oregon, Arizona and Washington State. Within this section you can read our statements about integrated care and patient first care.
Diagnostics & Tech Is Our Vision – The October 5th acquisition of Texas-based KAI Medical Laboratory was a significant achievement for Empower, as it firmly and immediately established the science and research side of Empower. In its first month, KAI delivered record revenues and soon after announced its first $1,000,000 COVID-19 testing contract for a major film and television studio.
This section is rich in information for investors that want to better familiarize themselves with the capabilities of KAI Laboratory and COVID-19 testing capabilities that attracted major contracts and R&D initiatives.
EMPOWER TO COMMENCE VERIFIED DISCUSSIONS BY CEO AND KEY PERSONNEL ON AGORACOM
The Company is commencing discussions on its “CEO Verified Forum” on AGORACOM, which is intended to serve as one of the Company’s social media platforms for interaction with current and prospective shareholders.
Steven McAuley added “The growth experienced by Empower over the past 12 months has come from all sources providing the best possible engagement with our clients, followers, investors and all social platforms. I enjoy responding to shareholder inquiries, and the demand for engagement and discussion by investors has grown significantly. Engaging with Agoracom followers is an invaluable tool given our anticipated developments and I look forward to posting my comments and interactions with shareholders.”
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients and provide long term value for our shareholders.
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
Posted by AGORACOM-JC
at 7:27 AM on Wednesday, December 9th, 2020
VANCOUVER, British Columbia, Dec. 09, 2020 — Loop Insights Inc. (MTRX:TSXV) (RACMF:OTCQB) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated venue tracing to the brick and mortar space, is pleased to announce the signing of a Memorandum Of Understanding (“MOU”) with SimpliFlying, the world’s leading aviation marketing consulting firm, to support specific near-term opportunities with world renown resorts, national tourism boards, major airlines, airports, cruise ships, and ports.
As a result of this success, existing discussions have significantly advanced with the following near-term Travel Bubble opportunities:
NATIONAL TOURISM BOARDS – Dominican Tourism, Cayman Islands Tourism, Bahamas Tourism, Jamaican Tourism, and Turks & Caicos Tourism Boards.
WORLD RENOWN RESORTS – Iberostar, Bahia Principe, and Hyatt Resorts.
Today’s partnership with SimpliFlying now accelerates the possibility for Loop to truly deliver Travel Bubble solutions on a global basis. With Empower Clinics already delivering diverse and dynamic testing solutions capable of processing thousands of tests per day from its world-class laboratory in Dallas, SimpliFlying provides the final piece that connects international airline carriers, airports, cruise lines, and ports that rely on SimpliFlying to provide them with the necessary solution providers, procedures, and protocols.
Loop Insights CEO Rob Anson stated “This partnership is a very important and powerful next step to accelerate Loop’s potential growth. With the Company’s recent launch of its first live venue events, with the whole world watching, including world-renown venues and hospitality companies, Loop hit it out of the park and provided the world with the empirical data necessary to demonstrate our bubble solution is nothing short of world-class. By adding the direct integration with Empower’s diverse testing capabilities and SimpliFlying’s network of large-scale customer projects, we have now commenced significant discussions surrounding travel bubble opportunities with some of North America’s largest airlines, resort operators, venues, and hospitality groups globally. We anticipate this new revenue stream may be significant for the Company as we progress these opportunities in 2021.”
SIMPLIFLYING IS A TRUSTED NAME TO AIRLINES, AIRPORTS, AND HOTEL GROUPS
SimpliFlying has been consulting to airlines for over a decade and is one of the largest in the world, having worked with over 100 airlines, OEMs, and airports globally with clients that include American Airlines, Turkish Airlines, LATAM Airlines, Airbus, Boeing, Bombardier, and Toronto Pearson Airport.
SimpliFlying also solves complex operational issues facing the airline and tourism industry, working with large hotel groups such as Intercontinental and others.
SIMPLIFLYING LAUNCH OF “SIMPLITESTED” RECEIVES EARLY PRAISE AS ONE OF THE MOST COMPREHENSIVE APPROACHES SO FAR
With the Coronavirus Pandemic wreaking havoc on the global airline and tourism industry, the work of SimpliFlying has become more important than ever in helping to solve how airlines, airports, cruise lines, hotels, and tourism will safely get back to operations. SimpliFlying is working closely with major international airlines and major Canadian airlines on “Travel Bubbles” and “Tourism Bubbles” that involve testing and tracing protocols throughout the travel supply chain.
To this end, SimpliFlying has just launched SimpliTested to highlight and support the needs of key industries around the globe, in partnership with FDA and CE-approved testing providers, reliable labs, and cutting edge exposure notification apps. The initiative has already received early praise from the media:
Shashank Nigam, Founder & CEO of SimpliFlying stated “The travel industry needs a consistent testing standard that is accurate, affordable and easy to self-administer, with reliable contact tracing. The SimpliTested solution disrupts and drastically improves COVID testing for travel in partnership with Empower Clinics and Loop Insights. Testing can be comfortable and contact tracing built-in to ensure the risk of community exposure is severely restricted. This instantly makes it more appealing to the average traveller, airlines, resorts, and the local tourism authorities.”
Steven McAuley, Chairman, and CEO of Empower stated “The prospect of vaccines becoming available will not diminish the need for comprehensive solutions for testing, contact tracing and strategic operational changes to so many industry and society processes and protocols. Loop Insights, SimpliFlying, and Empower’s testing products and lab capabilities represent exactly what is needed to get our economy working again. Loop Insights’ contact tracing solution is proven, effective and ties together data and workflow. SimpliFlying with its deep connections to airlines, airports, tourism and hospitality provide the strategic design of how our solutions must work together ensuring precise new workflows are implemented balancing health & safety with the most basic functional needs of travellers and operators.”
SimpliFlying is the world’s leading aviation marketing consulting firm, yet we behave like an agile startup. Our team is 100% remote-based in Singapore, Spain, UK, and Canada – meaning we can provide airlines with a global and a 24/7 presence. Since 2009, we have not only worked with an enviable list of aviation brands but also built a unique work culture that appeals to the disruptors in the industry. Our team is young, energetic, and brimming with ideas on how to make airlines remarkable. These are ideas based on over ten years of working with over 100 aviation firms and analyzing hundreds of aviation marketing campaigns monthly.
About Empower
Empower provides body and mind wellness for more than 165,000 patients through its clinics in the United States, a telemedicine platform, and a world-class medical diagnostics laboratory in Texas. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across the U.S. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
About Loop Insights
Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network.
This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Tags: AI, Amazon, artificial intelligence, Big data, covid19, Covid19 tracing, CSE, Fobi, internet of things Posted in Empower Clinics Inc., Loop Insights Inc. | Comments Off on Loop Insights $MTRX.ca $RACMF and Empower Clinics $CBDT.ca $EPWCF “Travel Bubble” Solution For Global Travel Industry Partner With SimpliFlying, World’s Leading Aviation Marketing Consulting Firm, To Support Specific Near Term Opportunities With World Renown Resorts, National Tourism Boards, Major Airlines, Airports, Cruise Ships, and Ports
Posted by AGORACOM-JC
at 7:28 AM on Tuesday, December 8th, 2020
Empower’s KAI Medical Laboratory Is A Priority Testing Partner That Is Expected To Participate In Significant Programs Aimed At Opening Up Key Travel and Hospitality Industries
Announced the signing of a Memorandum Of Understanding (“MOU”) with SimpliFlying, the world’s leading aviation marketing consulting firm, to provide COVID-19 testing support for airlines and travel bubbles.
SimpliFlying has been consulting to airlines for over a decade and is one of the largest in the world, having worked with over 100 major clients including airlines, OEMs and airports globally with clients that include American Airlines, Turkish Airlines, LATAM Airlines, Airbus, Boeing, Bombardier and Toronto Pearson Airport.
SimpliFlying also solves complex operational issues facing the airline and tourism industry, working with large hotel groups such as Intercontinental and others.
VANCOUVER, BC / December 8, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company serving a database of 165,000 patients through clinics in the Southwest United States, a telemedicine platform and a leading medical diagnostics laboratory is pleased to announce the signing of a Memorandum Of Understanding (“MOU”) with SimpliFlying, the world’s leading aviation marketing consulting firm, to provide COVID-19 testing support for airlines and travel bubbles.
SIMPLIFLYING IS A TRUSTED NAME TO AIRLINES, AIRPORTS AND HOTEL GROUPS
SimpliFlying has been consulting to airlines for over a decade and is one of the largest in the world, having worked with over 100 major clients including airlines, OEMs and airports globally with clients that include American Airlines, Turkish Airlines, LATAM Airlines, Airbus, Boeing, Bombardier and Toronto Pearson Airport.
SimpliFlying also solves complex operational issues facing the airline and tourism industry, working with large hotel groups such as Intercontinental and others.
SIMPLIFLYING LAUNCH OF “SIMPLI TESTED” RECEIVES EARLY PRAISE AS ONE OF THE MOST COMPREHENSIVE APPROACHES SO FAR
With the Coronavirus Pandemic wreaking havoc on the global airline and tourism industry, the work of SimpliFlying has become more important than ever in helping solve how airlines, airports, cruise lines, hotels and tourism will safely get back to operations. SimpliFlying is working closely with major international airlines and major Canadian airlines on “Travel Bubbles” and “Tourism Bubbles” that involve testing protocols using PCR tests, rapid PCR, rapid antibody and rapid antigen tests throughout the travel supply chain.
To this end, SimpliFlying has just launched SimpliTested to highlight and support the needs of key industries around the globe, in partnership with FDA and CE approved testing providers, reliable labs and cutting-edge exposure notification applications. The initiative has already received early praise from the media:
EMPOWER TO PROVIDE MARKET LEADING COVID-19 TESTING SUPPORT AND TRAVELLER ACCESS TO LABS ACROSS NORTH AMERICA
Shashank Nigam, Founder & CEO of SimpliFlying stated “To kickstart travel, airlines and airports need to offer easy access to labs that can turn around accurate test results in a speedy manner. SimpliFlying’s partnership with Empower Clinics will bring access to labs all across North America to support travellers.”
Empower will provide COVID-19 testing support with our most recent products launched in the United States including:
Empower will also provide additional critical functionality to support the strategic consulting work provided by SimpliFlying to airlines and the hospitality industry, including the ability to support onsite collection operational processes at airports, hotels and cruise lines.
Moreover, Empower has the ability to provide additional support for a variety of solutions that may require and are capable of delivering critical elements such as contact tracing technology.
Finally, both Companies intend to lead education and proof of concept with the goal of eliminating 14-day quarantine requirements upon return to Canada. Having structured policies and testing protocols to confirm that travellers are negative for the COVID-19 virus has the potential to significantly open up travel limitations.
Steven McAuley, Chairman and CEO of Empower stated “Once I made the connection with Shashank the SimpliFlying Founder & CEO, I knew right away that a partnership needed to be created given how complementary our companies are to each other. Shashank and team have impressed me with their technical knowledge of the airline, tourism and hospitality industries, they understand exactly what is required to get these key industries back on track, back to work, to get consumers traveling again. Together, utilizing the operational and testing protocols coming to market right now from our wholly owned subsidiary KAI Medical Laboratory, has the potential to make a meaningful and lasting impact on these global industries.”
PARTNERSHIP FURTHER SOLIDIFIES KAI MEDICAL FOOTHOLD IN COVID-19 TESTING SPACE
KAI Medical Laboratory operates a high-complexity CLIA and COLA accredited laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. KAI has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing with the capacity to process 4,000 RT-PCR test specimens per day. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.
As a result of this capability, Empower is now able to expand phase four of its COVID-19 testing rollout which was first announced on April 27, 2020 beginning with testing in-clinic testing (Phase 1) and culminating with a nationwide roll-out across the United States (Phase 4). Phase 4 allows Empower to service enterprise level clients, including airlines, hotels, cruise lines and movie & television studios that require reliable, accurate, fast and mass batch testing capabilities in order to resume production in a safe and compliant manner.
ABOUT SIMPLIFLYING
SimpliFlying is one of the world’s leading aviation marketing consulting firms with a team remote-based in Singapore, Spain, UK and Canada, with the ability to provide airlines with a global and a 24/7 presence. Since 2009, the company has worked with an enviable list of aviation brands and built a unique work culture that appeals to the disruptors in the industry. The team is energetic and brimming with ideas on how to make airlines remarkable. These are ideas based on working with over 100 clients over the past ten years.
ABOUT EMPOWER
Empower provides body and mind wellness for more than 165,000 patients through its clinics in the United States, a telemedicine platform and a world-class medical diagnostics laboratory in Texas. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across the U.S. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
ABOUT KAI MEDICAL LABORATORY
Our mission is to improve healthcare through science and innovative quality diagnostics, providing value added services, accuracy, and consistency. Operating with an unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to higher standards for patient care. Kai Medical Laboratory is located in the Dallas Medical District in close proximity to some of the largest healthcare groups in the U.S. including Parkland Hospital, UT Southwestern, Children’s Medical Center, Baylor Scott & White Health (Dallas), Tenet Healthcare (Dallas), CHRISTUS Healthcare (Dallas). KAI Medical Laboratory has completed clinical trials on novel COVID-19 testing protocols and assisted in supporting FDA and Health Canada submissions.
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the future potential success of Kai Medical Laboratory, Sun Valley’s future potential; whether a definitive agreement will be reached with SimpliFlying; or the ability of Empower’s wholly owned subsidiary Kai Medical Laboratory to successfully bring to market new test protocols; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
